Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced today that the Company has partnered with Microdose Psychedelic Insights a leader in B2B psychedelic intelligence, to present a free, three-part live video discussion series titled “Mydecine Speaker …
The first Mydecine Speaker Series event will feature Mydecine Scientific Advisory Board Members Dr. Robin Carhart -Harris and Dr. Ruth Lanius , Chief Medical Officer Rakesh Jetly and Chief Scientific Officer Robert Roscow
Moderated by Yeji Lee, Business Insider reporter, the panelists will discuss the impact of cutting edge research in mainstream medical interest about unlocking the potential of psychedelic therapies
Robert Roscow , Chief Science Officer of Mydecine to be named to Mydecine Board of Directors
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced today that the Company has partnered with Microdose Psychedelic Insights (“Microdose”), a leader in B2B psychedelic intelligence, to present a free, three-part live video discussion series titled “Mydecine Speaker Series” covering Research, Psychedelic Therapies, PTSD, Microdosing, and Drug Discovery.
Details and schedule of the first event are as follows:
|Title:||How cutting edge research is igniting mainstream medical interest to unlock the potential of psychedelic therapies|
|Panel:|| -Dr. Robin Carhart-Harris, Head of the Centre for Psychedelic Research, Division of Brain Sciences, Faculty of Medicine, Imperial College London
-Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, Chief Medical Officer, Mydecine Innovations Group
-Dr. Ruth Lanius, MD, PhD, Professor of Psychiatry and the director of the post-traumatic stress disorder (PTSD) research unit at the University of Western Ontario
-Robert Roscow, MA, Chief Science Officer & Co-Founder of Mydecine Innovations Group, Former head of genetic research for Canopy Growth and prior was the head of genetics at ebbu
|Moderator: ||Yeji Lee, Business Insider|
|Date:||December 15, 2020 at 12:00 p.m. – 1:30 p.m. Eastern|
“We are excited to introduce members of our Management and Scientific Advisory Board and give some insight into the incredible projects and direction they are focused on in this dynamic field. As key thought leaders in the community, their insights to the audience will be highly educational. In breaking down these key issues in drug development and other advances in research, we are able to foster a lively, informed debate among those leaders who are helping to shape the psychedelic industry,” said Joshua Bartch, CEO of Mydecine. “The more resources that are available to key stakeholders in this industry, the more we will see wider public acceptance of these important – and in some cases – life changing compounds.”
In each webinar, 3 to 4 featured thought leaders in the psychedelic space will give their expert perspective on the current and future research, findings and their applications to the marketplace. The participants will engage in deep and intimate conversations followed by a Q&A period with the audience.
We would also like to welcome Robert Roscow, CSO, to the Board of Directors for Mydecine Innovations Group. As one of the founders, his background and knowledge to help drive the vision for Mydecine is invaluable. His expertise and contributions around genomics, evolution and molecular biology around cannabinoids were key drivers to the success of ebbu and Canopy Growth. His work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone . Now, Mr. Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi.
About Mydecine Innovations Group
Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada.
On behalf of the Board of Directors :
Joshua Bartch, Chief Executive Officer
Corp Communication :
Charles Lee, Investor Relations
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
News Provided by GlobeNewswire via QuoteMedia